Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

TAUKLARIFY

Drug and asset intelligence for TAUKLARIFY with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
0
Stage
Development stage unavailable

Recent signals(2)

RegulatoryAugust 20, 2026

FDA Approval Letter for TAUKLARIFY (NDA 220496) by Cerveau Technologies

The FDA has issued an approval letter for TAUKLARIFY (NDA 220496), PET imaging agent developed by Cerveau Technologies.

RegulatoryAugust 19, 2026

FDA Approval Application for TAUKLARIFY by Cervaeu Technologies

Cervaeu Technologies has submitted an NDA for TAUKLARIFY (FLORQUINITAU F18) with a standard review priority, indicating that the FDA will evaluate the application under typical timelines.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Therapeutic areas

Imaging Agent →
Neurology →
Oncology →
PET Imaging Agent →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.